...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >A Comparison of the Efficacy, Tolerability and Safety of Azithromycin and Co-Amoxiclav in the Treatment of Sinusitis in Adults
【24h】

A Comparison of the Efficacy, Tolerability and Safety of Azithromycin and Co-Amoxiclav in the Treatment of Sinusitis in Adults

机译：阿奇霉素和阿莫西非联合治疗成人鼻窦炎的疗效，耐受性和安全性比较

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of non-severe acute maxillary/ethmoidal sinusitis were compared in a randomized, open clinical trial in 254 adult patients. The predominant pathogens were Streptococcus pneumoniae and Haemophilus influenzae (83 patients). Azithromycin was administered orally to 165 patients at a single daily dose of 500 mg for 3 days, and co-amoxiclav (4:1) to 89 patients, at a dose of 500 mg three times daily for 10 days. The overall clinical response rates were 87.5% for azithromycin and 83.7% for co-amoxiclav at follow-up (day 21–28). Microbiological responses to both drugs were good, with only five patients in each group having a persistent infection after treatment. Both drugs were well tolerated and produced similar incidences of adverse events, which were mostly gastrointestinal. Azithromycin was as effective, and as well tolerated as co-amoxiclav, and its shorter simpler dosing regime may offer advantages in compliance and cost.
机译：在一项随机，开放的254名成人临床试验中，比较了阿奇霉素和阿莫西非治疗非严重急性上颌/筛窦炎的疗效，耐受性和安全性。主要的病原体是肺炎链球菌和流感嗜血杆菌（83例）。每天以500 mg的单日剂量向165名患者口服阿奇霉素3天，以89 mg的阿莫西拉夫（4：1）口服剂量以500 mg每天3次，共10天。随访（21-28天）时，阿奇霉素的总临床反应率为87.5％，而阿莫西拉夫的总临床反应率为83.7％。两种药物的微生物学反应均良好，每组中只有五名患者在治疗后持续感染。两种药物均具有良好的耐受性，并产生相似的不良事件发生率，这些不良反应主要是胃肠道的。阿奇霉素与阿莫西拉一样有效，并且耐受性好，其较短的简单给药方案可能在依从性和成本方面提供优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号